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Abstract 1 
Natriuretic peptide (NP; B-type NP [BNP], N-terminal proBNP [NT-proBNP], and midregional 2 
proANP [MR-proANP]) concentrations are quantitative plasma biomarkers of the presence and 3 
severity of hemodynamic cardiac stress and heart failure (HF). End-diastolic wall stress, 4 
intracardiac filling pressures and intracardiac volumes seem to be the dominant triggers.  This 5 
paper details the most important indications for NPs and highlights eleven key principles 6 
underlying their clinical use shown below. 7 
• NPs should always be used in conjunction with all other clinical information. 8 
• NPs are reasonable surrogates for intracardiac volumes and filling pressures. 9 
• NPs should be measured in all patients presenting with symptoms suggestive of HF such as 10 
dyspnea and/or fatigue, as their use facilitates the early diagnosis and risk stratification of HF. 11 
• NPs have very high diagnostic accuracy in discriminating HF from other causes of dyspnea: 12 
the higher the NP, the higher the likelihood that dyspnea is caused by HF. 13 
• Optimal NP cut-off concentrations for the diagnosis of acute HF (very high filling pressures) 14 
in patients presenting with acute dyspnea to the emergency department are higher as compared 15 
to those used in the diagnosis of chronic HF in patients with dyspnea on exertion (mild increase 16 
in filling pressures at rest). 17 
• Obese patients have lower NP concentrations, mandating the use of lower cut-off 18 
concentrations (about 50% lower). 19 
• In stable HF patients, but also in patients with other cardiac disorders such as myocardial 20 
infarction, valvular heart disease, atrial fibrillation, or pulmonary embolism NP concentrations 21 
have high prognostic accuracy for death, and HF hospitalisation. 22 
• Screening with NPs for the early detection of relevant cardiac disease including left ventricular 23 
systolic dysfunction in patients with cardiovascular risk factors may help identify patients at 24 
increased risk therefore allowing targetted preventive measures to prevent HF.• BNP, NT-25 
proBNP, and MR-proANP have comparable diagnostic and prognostic accuracy. 26 
3 
 
• In patients with shock, NPs cannot be used to identify cause (e.g. cardiogenic versus septic 1 
shock), but remain prognostic. 2 
• NPs cannot identify the underlying cause of HF and therefore, if elevated, must always be 3 
used in conjunction with cardiac imaging. 4 
  5 
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1. Introduction   1 
Natriuretic peptides (NP; B-type natriuretic peptide [BNP], N-terminal proBNP [NT-proBNP]) 2 
are quantitative plasma biomarkers of the presence and severity of hemodynamic cardiac stress 3 
and heart failure (HF). This paper gives their most important indications and highlights key 4 
principles underlying their clinical use: 5 
NPs are of substantial medical value for the diagnostic evaluation of suspected HF.1,2 6 
This indication is supported by several diagnostic and randomised controlled studies and is 7 
consistently recommended in clinical practice guidelines.1,2 NPs also can help in a broad range 8 
of other indications, including prognostication of patients with established cardiovascular 9 
disorders such as myocardial infarction, valvular heart disease, HF, and pulmonary embolism.3,4 10 
Overall, BNP and NT-proBNP have comparable diagnostic and prognostic accuracy5–8; other 11 
natriuretic peptides such as ANP (or MR-proANP) are also comparable, but less well-12 
documented. Accordingly, all recommendations apply to the use of NPs in general. Though of 13 
substantial value for serially assessing prognosis in those with HF, randomised controlled 14 
intervention trials have provided inconsistent results regarding the medical value of using NP 15 
concentrations to guide treatment in patients with HF, rendering this indication controversial.9–16 
11 The purpose of this review is to provide clinicians with advice on the use of NP 17 
concentrations as a diagnostic aid in their daily practice.  18 
The concentrations of the three appropriately validated NPs (BNP, NT-proBNP, MR-19 
proANP) correlate closely with each other. However, their individual values are NOT 20 
interchangeable and their normal ranges and optimal cut-off concentrations differ.  21 
Two important principles should underlie the clinical use of NPs. First, a NP 22 
measurement should never be a stand-alone test. It is always of greatest value when it 23 
complements the physician's clinical skills along with other available diagnostic tools. Results 24 
should always be interpreted in consideration of renal function, and body mass index (BMI), 25 
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the two most powerful confounders of NP concentrations.12–20 Second, NP concentrations 1 
should be interpreted and used as continuous variables in order to make full use of the biological 2 
information provided by the measurement (similar to calculated glomerular filtration rate). Cut-3 
off concentrations may still be useful to make the application of NP easy for physicians without 4 
extensive experience with NP testing. 5 
Table 1. Key principles for the use of NPs in clinical practice. 6 
NPs should always be used in conjunction with all other clinical information. 7 
NPs are reasonable surrogates for intracardiac volumes and filling pressures. 8 
NPs should be measured in all patients presenting with symptoms suggestive of HF such as 9 
dyspnea and/or fatigue, as their use facilitates the early diagnosis and risk stratification of HF. 10 
NPs have very high diagnostic accuracy in discriminating HF from other causes of dyspnea: 11 
the higher the NP, the higher the likelihood that dyspnea is caused by HF. 12 
Optimal NP cut-off concentrations for the diagnosis of acute HF (very high filling pressures) in 13 
patients presenting with acute dyspnea to the emergency department are higher as compared 14 
to those used in the diagnosis of chronic HF in patients with dyspnea on exertion (mild increase 15 
in filling pressures at rest). 16 
Obese patients have lower NP concentrations, mandating the use of lower cut-off 17 
concentrations (about 50% lower). 18 
In stable HF patients, but also in patients with other cardiac disorders such as myocardial 19 
infarction, valvular heart disease, atrial fibrillation, or pulmonary embolism NP concentrations 20 
have high prognostic accuracy for death, and HF hospitalisation. 21 
Screening with NPs for the early detection of relevant cardiac disease including left ventricular 22 
systolic dysfunction in patients with cardiovascular risk factors may help identify patients at 23 
increased risk therefore allowing targetted preventive measures to prevent HF. 24 
BNP, NT-proBNP, and MR-proANP have comparable diagnostic and prognostic accuracy. 25 
In patients with shock, NPs cannot be used to identify cause (e.g. cardiogenic versus septic 26 
shock), but remain prognostic. 27 
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NPs cannot identify the underlying cause of HF and therefore, if elevated, must always be 1 
used in conjunction with cardiac imaging. 2 
HF: heart failure; NP: natriuretic peptide. 3 
 4 
2. Physiology 5 
Although NP levels can be modulated by lesser understood mechanisms, the most important 6 
one is in the setting of volume expansion and/or pressure overload: the resulting end-diastolic 7 
wall stress initiates synthesis of NP precursors in the ventricular and atrial myocardium. 12,21–25 8 
Further, BNP/NT-proBNP are exclusively produced by the cardiac tissue, and as such, NPs 9 
production reflects wall stress, a product of intracardiac volumes and filling pressures. Through 10 
binding to multiple NP receptors, NPs lead to natriuresis, diuresis, vasodilation, improved 11 
myocardial relaxation, and reduced myocardial fibrosis.26 Thus, NPs serve an important 12 
regulatory role by opposing the vasoconstriction, sodium retention, and antidiuretic effects of 13 
the activated renin–angiotensin–aldosterone (RAS) and sympathetic nervous systems.27 The 14 
biochemistry of NP release and breakdown is complex and is discussed elsewhere.28–32 15 
 16 
Figure 1 illustrates the haemodynamic determinants of NPs. 17 
 18 
A given NP concentration is a summation of many inputs and is a measure of many 19 
aspects of cardiac function. It is critically important to remember both BNP and NT-proBNP 20 
are not solely biomarkers of left ventricular (LV) systolic function; indeed, a broad range of 21 
structural and functional cardiac abnormalities may lead to meaningful elevation of NPs, 22 
including LV diastolic dysfunction, right ventricular dysfunction, valvular dysfunction, 23 
increased pulmonary pressures, and atrial arrhythmias.12,23,33–35 24 
 25 
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3. Diagnosis of HF 1 
The unmet clinical need: HF, a progressive disease with a mortality exceeding most cancers, 2 
presents a major burden to health care systems.36 Most patients with HF eventually present to 3 
the emergency department (ED) or hospital typically due to symptoms related to congestion. 4 
Because HF occurs predominantly in older subjects, its presentation is often complicated by 5 
multiple co-morbidities. This is unfortunate, since the most common presentation of HF is 6 
dyspnoea, a complaint that is neither specific nor sensitive for predicting the presence of HF. 7 
Additionally, though physical findings in HF such as bilateral basal pulmonary end-inspiratory 8 
rales, elevated jugular venous pressure, and leg oedema are relatively specific for the diagnosis, 9 
their sensitivity is limited (only 50-60%). Similar limitations apply to the ECG and chest x-ray. 10 
Accordingly, diagnostic uncertainty frequently remains high after clinical assessment.37–40 In 11 
the Breathing Not Properly study, at an 80% cut-off level of certainty of HF, clinical judgment 12 
had a sensitivity of only 49%.37 13 
The evidence: Diagnostic studies comparing measurements of NPs against a reference 14 
standard diagnosis of HF (or alternative diagnosis) have consistently shown that NPs have very 15 
high diagnostic accuracy for HF.16,41,42 Moreover, NPs improve the diagnostic accuracy of 16 
clinical judgment in the ED. This observation is also true for adults >75 years old despite the 17 
slightly diminished diagnostic accuracy for NT-proBNP in this age group.16 In addition, three 18 
randomised controlled trials have showed that earlier and more accurate diagnosis of HF 19 
translates into medical and economic value for patients, physicians, and the health care 20 
system.38,43,44 21 
Recommendation: NP should be measured in all patients presenting with symptoms 22 
suggestive of new-onset or worsening of HF such as dyspnea and/or fatigue, as their use 23 
facilitates both the early diagnosis or the early exclusion of HF. 24 
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Practical guidance: As a quantitative marker of HF, NP concentrations are best 1 
interpreted as a continuous variable: very low NP concentrations have a very high negative 2 
predictive value (NPV) to exclude the presence of HF. On the other hand, the higher the NP 3 
concentration, the higher the likelihood that dyspnea is due to HF.38,39,45,46 Also, optimal NP 4 
cut-off concentrations for the diagnosis of acute HF (very high filling pressures) in patients 5 
presenting with acute dyspnea to the ED are higher as compared to those used in the diagnosis 6 
of chronic HF in patients with dyspnea on exertion (mild increase in filling pressures at rest, 7 
Table 2). Combined with echocardiography in patients with elevated NPs, NP-testing enables 8 
the rapid and accurate diagnosis of HF, and its phenotypes (Figure 2).47 Given elevation of NPs 9 
occurs in critically ill patients such as shock (including that caused by sepsis), elevated 10 
concentrations are not specific for cardiogenic causes of shock; other diagnostic approaches 11 
including immediate echocardiography need to be used.  However, elevated NP concentrations 12 
in shock of any cause are prognostic.48,49 In patients with an established diagnosis of HF, the 13 
measurement of NPs is not nessessery at all follow-up visits but whenever it is unclear whether 14 
and to what extent the reported symptoms are related to HF. 15 
 16 
Figure 2. Diagnostic algorithm for HF. 17 
 18 
In patients with suspected acute HF, a BNP cut-off concentration of 100 pg/mL provides 19 
an excellent NPV to exclude the presence of HF, while higher values >400 pg/mL deliver 20 
excellent positive predictive value (PPV).39 As NT-proBNP shows a stronger correlation with 21 
age and renal dysfunction, age-dependent rule-in cut-offs are preferred for NT-proBNP 22 
(450/900/1800 pg/mL),41 while independent of age a NT-proBNP <300 pg/mL provides a very 23 
high NPV for HF. These results were recently affirmed.16,17  24 
Considering   “rule-in” thresholds requires addressing the fact that NPs may be 25 
persistently elevated in chronic HF and may not be representative of an acute haemodynamic 26 
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change. Knowledge of each patient’s individual NP concentration when stable (the so-called  1 
“dry” NP concentration) helps to interpret concentrations of these markers when such patients 2 
present with acute symptoms; a change of 100% or more from the stable concentration suggests 3 
a change in clinical state, such as decompensation.50,51   4 
When confronted with an elevated NP, other conditions that result in an increased 5 
concentration of these peptides should also be considered, including both those that result in 6 
myocardial end-diastolic wall stress  (acute pulmonary embolus, acute coronary syndrome, 7 
primary pulmonary hypertension, etc.) and renal failure, and therefore also represent HF per 8 
se.52 9 
 10 
3.1 Caveats in using NP levels 11 
3.1.1 “Grey zone” 12 
The “grey zone“ is defined in Table 2. 13 
Table 2. Recommended NPs` cut-offs for the acute HF diagnosis* 1,12,16,39 14 
 Cut-off levels (pg/mL) 
NT-proBNP BNP 
Age <50 Age 50-75 Age >75 Age <50 Age 50-75 Age >75 
Acute setting, patient with acute dyspnea 
HF unlikely <300 <100 
„Grey zone“ 300–450 300–900 300–1800 100–400 
HF likely >450 >900 >1800 >400 
Non-acute setting, patient with mild symptoms 
HF unlikely <125 <35 
„Grey zone“ 125-600 35-150 
HF likely >600 >150 
HF: heart failure; BNP: B-type natriuretic peptide; NT-proBNP: amino-terminal BNP 15 
*consider reducing the cut-off levels in obese patients by 50%.  16 
The grey zone needs extra physician attention and ancillary testing. While the final 17 
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diagnosis is often mild to moderate HF,39,53–55, or HFpEF rather than HFrEF, other causes of a 1 
modest rise in NP level should be considered. In acute dyspnoea, “grey zone” NP values are 2 
present in 20% of patients and about 50% of these will have acute HF. Other causes include 3 
primary non-cardiac pathology that causes myocardial stress, and includes pulmonary 4 
hypertension and RV dysfunction secondary to pulmonary embolism, pneumonia, and cor 5 
pulmonale.56–58  6 
The grey zone levels are far more strongly associated with HF when concomitant 7 
clinical features are present, such as a history of heart failure, jugular venous pressure, and prior 8 
diuretic use.55 9 
 10 
3.1.2 Pulmonary disease 11 
In patients with chronic pulmonary disease, differentiating between pulmonary causes of 12 
dyspnoea versus confounding cardiac disease can be clinically challenging. Importantly, 13 
previously unsuspected, “masked”, HF may be present in those with COPD. In this context, 14 
elevation of NPs may be useful to identify presence of unrecognized HF however it is necessary 15 
to remember in patients with pulmonary hypertension and RV dysfunction (e.g. in severe 16 
COPD), NP levels are often in the grey zone and occasionally in the diagnostic zone for HF, 17 
reflecting the existence of major RV stress and, in effect, right HF.56,57,59–63 The accuracy of NP 18 
to diagnose HF is unchanged in the presence of pre-existing pulmonary disease.58,62,63 19 
 20 
3.1.3 Renal disease 21 
There is an important interrelationship between cardiac and renal dysfunction. About one third 22 
of outpatients with chronic HF have renal dysfunction.64 Current data suggest that the cause of 23 
elevated NP concentrations in renal dysfunction is multifactorial, representing in part a true 24 
counter-regulatory response from the heart to the kidney, and not only diminished passive renal 25 
clearance.15,46 It is a major misconception that NPs are solely removed from circulation by the 26 
kidneys; indeed only 25% of clearance of NPs is related to renal filtration,20 with the balance 27 
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of their clearance due to  removal by various organs with high blood flow.65 In order to maintain 1 
optimal diagnostic performance, the cut-off concentrations for detecting HF may need to be 2 
raised when estimated glomerular filtration rate (eGFR) is less than 60 ml/min.46 Due to the 3 
strong correlation between renal dysfunction and age, no additional adjustment seems 4 
nessessary for NT-proBNP once using age adjusted rule-in cut-offs. For BNP, the impact of 5 
renal dysfunction overall is smaller, and increasing the rule-out ut-off tp 200 pg/ml rather than 6 
100 pg/ml seems sufficient.46 Overall, it is imiportant to highlight that renal dysfunction and its 7 
associated cardiac comorbidities, and not age per se, seem to be the major driver behind the 8 
higher NT-proBNP and BNP  concentrations in elderly patients.14 Due to incomplete data, NP 9 
testing for HF should be discouraged in patients on dialysis. Importantly, high NP 10 
concentrations should not be ignored in the setting of renal dysfunction.66 Given the strong 11 
relationship between cardiac and renal disease, clearly elevated NP concentrations suggest that 12 
cardiac disease is present and should influence clinical decision-making. 13 
 14 
3.1.4 Diastolic dysfunction 15 
In accord with the cardinal role of myocyte stretch in generating NP synthesis and release, the 16 
severity of diastolic dysfunction is correlated to increased plasma concentrations of both BNP 17 
and NT-proBNP.67,68  18 
 19 
3.1.5 Atrial arrhythmia 20 
It is well-established that the presence of atrial arrhythmias such as atrial fibrillation or flutter 21 
are associated with higher concentrations of NPs.69 On occasion, the values of these peptides 22 
may be in excess of the threshold for  “HF”, even in the absence of further clinical support for 23 
the diagnosis.70 In those presenting with recent onset dyspnoea and concurrent atrial fibrillation, 24 
HF is present in at least 65 % of cases. From a pathophysiological and clinical perspective, 25 
these patients should be considered to have HF until proven otherwise. Subclinical myocardial 26 
stress must be assumed in such patients regardless of results from echocardiography. In addition, 27 
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the onset of atrial arrhythmia is a common cause of decompensated HF, and in the presence of 1 
such an arrhythmia, HF is often more severe and associated with a worse prognosis.71 An even 2 
more elevated plasma level of BNP or NT-proBNP in those with atrial fibrillation or flutter is 3 
speculated to be due to release of peptide produced in the atria, however increased ventricular 4 
myocardium release, owing to higher wall stress from tachycardia, is also possible.72 5 
 6 
3.1.6 Patients treated with sacubitril/valsartan 7 
Sacubitril/valsartan seems to affect the concentration of NPs that are cleared by neprilysin such 8 
as BNP and ANP also by its direct pharmacologic effect on neprilysin (inhibition) and not only 9 
by its effect on intracardiac filling pressures.73–75 While the mechanisms underlying the effect 10 
of sacubitril/valsartan on NP concentrations and NP activity are a matter of ongoing 11 
research,76,77 at this point in time we consider NT-proBNP the preferred biomarker to quantify 12 
HF severity and monitor prognosis in patients on sacubitril/valsartan.33  13 
3.1.7 Patients with acute and chronic ischemia 14 
Natriuretic peptides independently and accurately predict mortality in patients with acute 15 
coronary syndrome (ACS), but do not seem to provide added diagnostic information.78–80 16 
Similarly, natriuretic peptides do not further increase diagnostic accuracy on top of clinical 17 
judgment and/or troponin measurements in the detection of inducible myocardial 18 
ischemia.81,82 It is currently unclear how the pathophysiological signals quantified by the 19 
elevation of natriuretic peptides in ACS patients could be best used clinically, in order to 20 
mitigate the identified high mortality risk.78,83 21 
3.2 Caveats: lower than expected concentration of natriuretic peptides 22 
3.2.1 Obesity 23 
Concentrations of both BNP, NT-proBNP, and MR-proANP are lower in obese persons, both 24 
with and without HF.84–87 Although the reason for this interaction remains incompletely 25 
understood (possibly including pericardial fat),86,88 given different mechanisms of clearance for 26 
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BNP, NT-proBNP and MR-proANP, this finding is most likely due to lower release of NPs in 1 
obesity, rather than increase in their clearance. Furthermore, with substantial weight loss, rise 2 
in NP concentrations are seen, implying a ‚de-repression‘ of their lower values.89 3 
Mechanistically, this may be due to suppression of the bnp gene by circulating factors such as 4 
androgens that may be produced by adipose tissue.90 It is noteworthy a unique relationship 5 
exists between BNP and adipose tissue: increased concentrations of NP receptors are found on 6 
adipocytes, and BNP induces lipolysis. This has led some to postulate that increased clearance 7 
might add to lower BNP levels in obesity,91,92 but given absence of clearance of NT-proBNP 8 
by NP receptors, this cannot entirely explain the inverse association between body-mass index 9 
(BMI) and NP concentrations. Clinically, caregivers should recognize risk for lower NP 10 
concentrations in those with BMI ≥30 kg/m2; such values are typically not “normal”, and more 11 
often closer to diagnostic thresholds than not. To optimize diagnostic accuracy, lowering of 12 
established cut-off concentrations by up to 50% in obese patients is reasonable.18 As there 13 
is a linear decrease in NP levels with increasing BMI, the higher the BMI the lower the cut-off 14 
concentration which provides the highest accuracy.18,67 A very low BNP cut-off concentration 15 
(<50 pg/mL) should be used to rule-out HF in obese patients. Neglecting this concept would 16 
invariably result in suboptimal sensitivity.93 Recently, it was demonstrated that the differenbces 17 
ascribed to obesity are in part explained by sex differences: men have lower NP levels than 18 
women, but weigh much more.78 Given the large overlap between obesity and HFpEF, and the 19 
generally lower levels of NP even in non-obese HFpEF, this aspect is particularly important for 20 
the diagnosis of HFpEF.93–95 Despite the lower circulating levels, NP levels retain prognostic 21 
performance in obese as well as HFpEF patients.18,67,96,97 22 
 23 
3.2.2 HF due to causes upstream from the LV 24 
When HF is due to a cause upstream from the LV, for example in mitral stenosis or acute mitral 25 
regurgitation, NP concentrations may be initially low despite severe symptoms. The absence of 26 
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a significant rise in LV wall stress in these acute settings explains the lack of marked NP 1 
production, and while NP levels may still be higher than normal, they will not rise to the same 2 
degree as when the HF occurs with a concomitant overload on the LV. Similarly, pericardial 3 
abnormalities, such as constriction and tamponade, can sometimes cause symptoms of HF; 4 
however, since the myocardial wall is not abnormally stressed, NP levels are typically normal 5 
or only slightly elevated.98,99 Early echocardiography is mandatory whenever suspecting HF 6 
due to a cause upside the LV such as mitral stenosis as well as in suspected pericardial 7 
tamponade.  8 
 9 
3.2.3 Flash pulmonary oedema 10 
NP levels may be relatively low in patients presenting with HF symptoms that develop abruptly, 11 
e.g. within one hour. In this setting, the time interval between the initial trigger and the 12 
measurement of NP levels is so short that it precedes the up-regulated peptide synthesis. Since 13 
only very small quantities of BNP (compared to atrial natriuretic peptide) are stored in secretory 14 
granules, the development of elevated BNP concentrations in “flash” pulmonary oedema is 15 
dependent upon the de novo synthesis and secretion of the peptide.100 The incidence of this 16 
phenomenon seems to be very low, given underlying sub-critical congestion in those who 17 
subsequently develop “flash” pulmonary edema.38,39,101,102 18 
 19 
3.2.4 Fatigue 20 
In some patients with HF, fatigue is the dominant symptom, while dyspnea is mild or even 21 
absent. The diagnostic performance of NP and the optimal cut-off concentrations of NPs in this 22 
setting are less well established as compared to patients with dyspnea as the key symptom.1,2  23 
15 
 
 1 
3.3 Natriuretic use in the community: linking primary and secondary care 2 
Background: While first coming to prominence in the acute setting, it is in the community that 3 
NP may have its widest application. Presently, there are three clinical settings where one should 4 
consider using NPs with varying levels of proof or guideline support. 5 
 6 
3.3.1 Established role: diagnosing HF 7 
Diagnosing new-onset HF in the community can be challenging. Suggestive symptoms are 8 
common, but often non-specific and physical signs often unremarkable. It is here that NP can 9 
be very helpful to the physician. Much as in the ED setting, evaluation of dyspnea often is 10 
challenging, with numerous diagnostic possibilities. Accordingly, use of NPs to clarify 11 
diagnostic evaluation in less acute settings has the same rationale. Although the number of 12 
studies in primary care is smaller as compared to those performed in the ED, most of the 13 
concepts and findings already discussed regarding use of NPs for diagnostic evaluation of HF 14 
in the ED also apply in outpatient testing, including the importance of cardiac and non-cardiac 15 
variables influencing concentrations of these peptides. Nonetheless, current evidence strongly 16 
supports the use of NP testing also in primary care for the correct evaluation of HF.103–107 17 
NP-testing in primary care is widely available both point-of-care, as well as using 18 
locally established sample pathways to central laboratories. It empowers the position of the GP 19 
and provides important guidance for linking primary and secondary care. 20 
In general, owing to their lower concentrations in the primary care setting, the main 21 
application of NPs for outpatient use has focused on their sensitivity and NPV; lower 22 
concentrations (e.g. BNP <35 pg/mL; NT-proBNP <125 pg/mL; MR-proANP <85 pmol/L) 23 
exclude HF with high confidence, whilst higher concentrations require further evaluation.108 A 24 
normal value has an excellent NPV and while an abnormal value does not confirm the diagnosis 25 
of HF, it does underline the need for further diagnostic tests, in particular Doppler-26 
echocardiography. Cut-off concentrations used to rule-out HF vary somewhat, dependent on an 27 
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agreed strategy of focusing on a strong rule-out test or a value that minimizes false positive 1 
results. At present the ESC guidelines recommend a cut-off concentration of 35 and 125 pg/ml 2 
for BNP and NT-proBNP respectively, a strategy that favours minimizing false negative results. 3 
For NT-proBNP, a stratified approach of 50/75/250 pg/mL for ages <50/50-75/>75 years may 4 
be considered as an alternative.1,109 5 
 6 
3.3.2 Emerging role: NP-screening to prevent HF 7 
Rational: HF prevention will play an increasingly important role in our strategies for the 8 
management of this syndrome. A significant challenge in this effort will be the requirement to 9 
individualise risk beyond the presence of accepted risk factors. NPs have been shown to be a 10 
strong independent indicator of new onset HF and other CV disease.110 Thus, beside their 11 
diagnostic value, low NP concentrations provide useful reassurance to the clinician regarding 12 
lower potential cardiovascular risk; this, in turn may be useful for triage decision making. 13 
The success of a population-based screening programme for a disease condition is dependent 14 
on disease prevalence, the availability of a screening test that is acceptable, safe and 15 
inexpensive, the presence of effective treatment for detected disease, as well as the existence 16 
of, and compliance with, a follow-up care system for people at risk or with positive tests.111 17 
NPs are attractive candidates for screening the general population for subclinical disease for 18 
several reasons. First, LV dysfunction and the other cardiovascular diseases that are detectable 19 
by elevated NP levels are common and cause significant morbidity and mortality.112 Second, 20 
NP levels may be elevated early in the disease process, allowing for timely detection of disease 21 
prior to symptom onset.113 Third, early treatment of latent disease with medications such as 22 
angiotensin converting enzyme inhibitors improves outcomes by preventing the development 23 
of symptomatic HFrEF.114 Notably, natriuretic peptides have limited accuracy in the screening 24 
for mildly reduced LV ejection fraction in asymptomatic patients.115  Finally, several studies 25 
have shown that, in the right setting, screening with NPs may prove cost-effective.116–118 26 
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 1 
Evidence: randomized controlled intervention studies 2 
Recently, the St. Vincent's Screening To Prevent Heart Failure Study (STOP-HF) project 3 
demonstrated that NP-defined risk and intervention reduced new onset HF, asymptomatic LV 4 
dysfunction and overall MACE among participants with cardiovascular risk factors (mean age 5 
65 years) recruited from 39 primary care practices.113 Intervention-group participants with BNP 6 
levels of 50 pg/mL or higher underwent echocardiography and collaborative care between their 7 
primary care physician and specialist cardiovascular service. A total of 263 patients (41.6%) in 8 
the intervention group had at least 1 BNP reading of 50 pg/mL or higher. The intervention 9 
group underwent more cardiovascular investigations and received more renin-angiotensin-10 
aldosterone system-based therapy at follow-up (control, 49.6%; intervention, 56.5%; P=0.01). 11 
The primary end point of LV dysfunction with or without HF was met in 59 (8.7%) of 677 in 12 
the control group and 37 (5.3%) of 697 in the intervention group (odds ratio [OR], 0.55; 95% 13 
CI, 0.37-0.82; P=0.003). The incidence rates of emergency hospitalization for major 14 
cardiovascular events were 40.4 per 1000 patient-years in the control group vs 22.3 per 1000 15 
patient-years in the intervention group (incidence rate ratio, 0.60; 95% CI, 0.45-0.81; 16 
P = .002).113 17 
These results were further strengthened by the NT-proBNP Guided Primary Prevention of CV 18 
Events in Diabetic Patients (PONTIAC) trial in 300 patients with type 2 diabetes (mean age 68 19 
years), elevated NT-proBNP (>125 pg/mL) but free of cardiac disease.119 The “control” group 20 
was cared for at 4 diabetes care units; patients randomized to the “intensified” group were 21 
additionally treated at a cardiac outpatient clinic for the up-titration of renin-angiotensin system 22 
(RAS) antagonists and beta blockers. The primary endpoint, hospitalization/death due to 23 
cardiac disease after 2 years, was significantly reduced in the intensified group. 24 
 25 
Evidence: diagnostic studies using echocardiography as the reference 26 
Many people with substantial LV dysfunction do not have typical symptoms, but might be 27 
18 
 
identified by a simple screening test such as BNP/NT-proBNP.120 Although echocardiography 1 
is the current gold standard for detection of LV systolic dysfunction and many other structural 2 
cardiac abnormalities, its cost, limited availability, and complexity in assessing LV diastolic 3 
dysfunction make it an impractical choice for population screening. Several investigations have 4 
evaluated the use of NP concentrations to identify asymptomatic subjects with  reduced LV 5 
ejection fraction,115,121,122 or for a broader range of sub-clinical cardiovascular disorders.116 6 
Thus, some of these findings demonstrate suboptimal accuracy of NPs as a screening test for 7 
LV systolic dysfunction in community cohorts.115 In the STOP-HF trial, about 3 patients with 8 
cardiovascular risk factors had to be screened to detect one patient with BNP concentration > 9 
50 pg/ml, which triggered cardiac work-up.113 Overall, applying BNP screening using this 10 
specific cut-off in the STOP-HF population resulted in a very favourable cost-effectiveness 11 
with €1,104 per quality-adjusted life year gain as cardiovascular hospitalization savings offset 12 
increased outpatient and primary care costs.123 13 
Recommendation: NP measurement by GPs and diabetologists in high risk populations such 14 
as those with hypertension or diabetes mellitus helps targeted initiation of preventive 15 
measures including medicine up-titration of RAS antagonists and thereby prevent or slow the 16 
development of HF. 17 
 18 
 19 
 20 
 21 
Figure 3. NP-screening in patients at high cardiovascular risk by GPs and diabetologists is an 22 
integral component of integrated patient care pathways aiming to prevent and/or early detect 23 
cardiovascular disease including heart failure (HF).  24 
 25 
 26 
3.3.3 Additional role: assessing new symptoms in HF 27 
NP assessment can be a very useful investigation in the community when assessing clinical 28 
deterioration in patients with established HF. These clinical settings can be challenging 29 
especially since features can be non-specific and potentially explained by co-morbidities. In 30 
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these circumstances, a significant increase in NP above a stable baseline value would support 1 
HF as the cause of deterioration, with no significant change from the stable value having the 2 
opposite, but equally-important implication. For this to be applied effectively values for NP 3 
reflecting the clinically stable state need to be available in the patients record for comparison 4 
and would need to be updated regularly.124,125 5 
 6 
3.3.4 Challenges to use of NP in the community  7 
The major challenge will be knowledge transfer to end-users, to ensure that the nuances of NP 8 
interpretation and the influence of multiple confounders are understood. While a very useful 9 
biomarker, NP results may be open to misinterpretation, thus potentially leading to incorrect 10 
decision-making. As in all other settings, frequent modifiers of NP include atrial fibrillation, 11 
renal failure, sepsis, and obesity. Above all else an understanding that a biochemical change 12 
value of at least 50% is required for acceptance that the change is likely of clinical relevance.  13 
 14 
4. Monitoring prognosis during HF therapy 15 
4.1 Predischarge during hospitalisation for acute HF 16 
Rationale: With current management, patients hospitalised for AHF continue to have 17 
unacceptably high rates of mortality and morbidity.1,2,12,126,127 Patients who are admitted to the 18 
hospital with acute HF usually respond symptomatically to treatment, but clinical assessment 19 
is unable to assess whether the optimal filling pressures have been achieved. Multiple studies 20 
have shown that many patients are discharged while still congested and the extent of remaining 21 
congestion is associated with mortality and the risk for another HF hospitalisation.128,129 The 22 
fact that NPs have a short half-life, are easily measured, and provide a quantitative marker of 23 
HF severity and prognosis, suggests that they might be a useful guide to judging the success of 24 
therapy in acute HF. The goals of using BNP or NT-proBNP is to determine whether a patient 25 
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has received adequate decongestive therapy and if their risk for rehospitalisation has been 1 
reduced as much as is feasible during their acute treatment. 2 
NP concentrations after treatment have prognostic significance: those with lower values 3 
at the time of discharge (or achieving greater relative reduction) have substantially better 4 
prognosis than those who are released from acute care with higher concentrations.130,131 5 
Discharge NP concentrations seem to be the best predictor of 1-year death or rehospitalisation 6 
among patients with acute HF, superior to admission values or the change in levels from 7 
admission to discharge.131,132 8 
Although there are few data defining why NP levels do not decline in some patients 9 
despite treatment, several clinical scenarios should be considered. First and most importantly, 10 
a persistently elevated NP concentration in a stably diuresed patient may actually be the 11 
patient's optivolaemic (dry) NP level at this time point due to persistent increased ventricular 12 
wall stress necessary to maintain adequate cardiac output.  This identifies a treatment-resistant, 13 
high risk patient with a poor prognosis. Another possible scenario is that a patient with 14 
concomitant right-sided HF and significant ascites and/or oedema might diurese many litres 15 
further before NP levels actually drop. This is likely due to mobilization of third-space fluid 16 
rather than lowering of cardiac filling pressures. Continuing diuresis and/or vasodilatation 17 
should eventually lower “wet” NP levels. Finally, in some cases treatment simply does not 18 
effectively correct central cardiac haemodynamic abnormalities and therefore does not improve 19 
cardiomyocyte stress and one should not expect, therefore, to see a decline in this setting; again, 20 
this is a high risk patient. 21 
It remains as yet unclear if changing therapy based on measured predischarge NP 22 
concentration can reduce rehospitalisation or avert death.9,133 A recent modest size randomised 23 
controlled pilot study was unable to document medical benefit, however in both study arms, 24 
those with a substantial reduction in NT-proBNP had superior outcomes to “non-responders”. 25 
Common sense would thus dictate for such higher risk patients that do not exhibit responsive 26 
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NP concentrations after treatment that more aggressive monitoring and therapy may be wise. 1 
Pre-discharge NP levels appear to be more cost-effective than comprehensive Doppler-2 
echocardiographic examination for the prediction of future cardiac death or HF re-3 
hospitalisation.134 It is reasonable to measure NP levels routinely prior to discharge when 4 
optivolaemic status seems to have been achieved by clinical assessment. This also sets a 5 
baseline for continued monitoring in the outpatient setting, where NP measurement may be 6 
continued. It further allows for individualising decision making regarding timing, frequency 7 
and intensity of follow up; those patients with a significant reduction in NP concentration after 8 
acute HF treatment are likely to have a benign early post-discharge course, whereas those with 9 
higher or non-falling concentrations may merit close follow up, including potential monitoring 10 
in the home.135 However, this indication is still controversial as a small small prospective 11 
randomized trial showed neutral results.10 12 
 13 
4.2 During outpatient visits for chronic HF 14 
Rationale: The concept of serial measurement of NPs as a quantitative measure of HF severity 15 
during outpatient visits for chronic HF mirrors the serial measurement of other key biomarkers 16 
in other settings such as e.g. eGFR in patients with kidney disorders, arterial blood pressure in 17 
arterial hypertension, and blood glucose and HbA1c in diabetes mellitus. Accordingly, serial 18 
measurements of NP would allow physicians to empower, educate and motivate HF patients, 19 
similar to the use of other disease surrogates in chronic disease such as home blood pressure, 20 
blood glucose, and HbA1c. Serial measurement of NPs provides useful and incrementally 21 
powerful prognostic information when measured in patients with chronic HF, not only in the 22 
setting of HFrEF but also in HFmrEF and HFpEF.73,96,97,136,137 Changes in NPs over time in 23 
patients with chronic HF not only prognosticate risk for adverse outcomes such as 24 
hospitalisation or death, but also predicts changes in LV size and function.137,138  25 
Though useful, several caveats exist regarding the interpretation of NP concentrations 26 
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in outpatient risk monitoring.  When a change in a NP concentration is not accompanied by a 1 
change in clinical status, this might reflect biological variability or a change in cardiac or renal 2 
function that has not yet resulted in symptoms or signs. As a result of both analytical and 3 
biological variabilities (haemodynamic, renal, etc.), reference change values (RCV) have been 4 
reported to be relatively large for NPs, up to a doubling of results for each biomarker.139–141 5 
Only one study investigated both chronic HF patients and normal subjets. The other studies 6 
only studied normal subjects, where very low NP concentrations were expected and small 7 
changes were very likely to be within the domain of biological and/or analytical variation. Any 8 
discussion of biological variation in HF is immediately undermined by the fact that present 9 
pathological changes determining NP concentration might be challenging to non-invasively 10 
measure, such as filling pressures. Accordingly, a more accurate question to ask is: "How much 11 
change in NPs must occur to identify presence of change in filling pressures?“ In this regard, 12 
among HF patients, a change of 50% seems to indicate a shift in filling pressure.23 Furthermore, 13 
it has been demonstrated that even a considerably small change in weight can trigger a 14 
substantial NP alteration.125 15 
The combination of symptoms, weight gain, and NP concentration may be the best way 16 
to diagnose early decompensation. As for inpatients, proper adjustment of HF management 17 
requires NP to be measured together with renal function. 18 
Therapies for HF, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin 19 
II receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA), beta blockers, 20 
diuretics, cardiac resynchronization therapy (CRT), and exercise all tend to chronically reduce 21 
concentration of NPs in parallel with their benefits; the sole exceptions to this rule include the 22 
effect of sacubitril/valsartan on BNP metabolism, where therapy tends to modestly raise 23 
concentration of the NP and the early NP raising effect of non-vasodilating beta blockers during 24 
their introduction and early titration.142 25 
The relationship between therapies for HF, drop in the NP concentrations and the 26 
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improvement in patient's symptoms, improved LV function, and subsequent outcome has led 1 
to the hypothesis NP-guided treatment might assist in adjusting chronic HF therapy. Despite 2 
the neutral results of the Guiding Evidence Based Therapy Using Biomarker Intensified 3 
Treatment in HF (GUIDE-IT) trial, a recent meta-analysis of all published RCTs to date is 4 
suggestive of benefit of a NP guided treatment adjustment approach for all-cause mortality in 5 
HFrEF patients (Figure 4).10,11,143 6 
Figure 4. All-cause mortality comparison of NT-proBNP–guided versus standard 7 
therapy in chronic HFrEF. 8 
In general, it is necessary to recognize the efficacy of any guide to therapy will be most 9 
realized in patients that are not receiving adequate, guideline-compliant medical therapy. In 10 
other words, those patients managed with aggressive application of therapies for HF might not 11 
realise as much benefit from NP measurement to "guide" their care although NP concentrations 12 
maintain their prognostic meaning in such patients. 13 
Current understanding of NP-guided HF care suggests the benefit of the approach is 14 
most obvious when: 1) a low target NP concentration is attempted (BNP <100 pg/mL; NT-15 
proBNP <1000 pg/mL), 2) therapies must be adjusted to achieve these goals (i.e. if an elevated 16 
NP concentration is ignored, the concept of "guiding therapy" is more likely to fail), and 3) a 17 
change in therapy would not have otherwise been made if NP measurement had not been 18 
performed. Studies that have these characteristics suggest the approach might improve outcome 19 
compared to usual care. On the other hand, in studies with very aggressively applied usual care, 20 
the approach of NP guidance might not be as likely to further improve outcomes.10,144,145 21 
Since the first randomised pilot study of 69 patients with HF and systolic LV 22 
dysfunction showing that therapy guided by NP levels reduced total cardiovascular events and 23 
delayed time to first event other trials have provided useful insights regarding the approach, 24 
and pooled analyses suggest benefit toward reduction in mortality even considering recent 25 
neutral trials.10,11,144,146 26 
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In the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With 1 
Congestive Heart Failure (TIME-CHF) trial of elderly patients,147 NP guided HF therapy did 2 
not significantly reduce the primary endpoint of 18-month survival free of all-cause 3 
hospitalisations (HR=0.91; P=0.39), however survival free of HF hospitalisation was reduced 4 
(HR=0.68; P=0.01), particularly in patients aged <75 years (interaction P <0.02). This finding 5 
has led to recognition of the importance of comorbidities on ability to achieve optimal 6 
medication titration (and thus, reduction in NT-proBNP or BNP); as older patients are more 7 
likely to have more complex medical conditions limiting application of guideline-directed 8 
medical therapies for HF, it is hardly surprising such patients are less likely to respond to NP 9 
guided HF care.148,149 The ProBNP Outpatient Tailored Chronic HF Therapy (PROTECT) trial 10 
provided useful pilot data regarding value of NT-proBNP guided HF care.150 In this study of 11 
151 patients with HF and reduced ejection fraction, NT-proBNP guided care with a goal value 12 
of <1000 pg/mL reduced total cardiovascular events compared with usual care (58 events vs. 13 
100 events, p=0.009; logistic odds for events 0.44, p=0.02). 14 
Most recently, the GUIDE-IT study, reported neutral results regarding NT-proBNP 15 
guided care.10 This trial was the largest randomized study to date, examining 894 subjects with 16 
HF with reduced ejection fraction treated with either a goal NT-proBNP <1000 pg/mL versus 17 
usual care. After a median 15 months of follow up, no benefit of NT-proBNP guidance versus 18 
usual care was seen (HR 0.98; P = 0.88). Furthermore, this strategy of NT-proBNP-guided HF 19 
therapy had higher total costs and was not more effective than usual care in improving quality 20 
of life outcomes.151 Notably, those patients in the usual care arm were seen an average of 10 21 
visits during follow up, had similar medication doses administered compared to the NT-proBNP 22 
arm, and achieved greater reduction in NT-proBNP concentrations when compared to other 23 
trials in this topic; this has led some to speculate more than standard intensity treatment was 24 
delivered to those in the usual care arm and conversely that therapy in the marker-guided arm 25 
of GUIDE-IT was not as aggressive as the trial protocol would appear to dictate.152,153 26 
25 
 
Accordingly, in populations of patients with lesser aggressive application of standard HF 1 
medication, it would still seem likely that NP measurements facilitate HF care. 2 
In addition, as outlined in 3.3.4, it is important to highlight that nearly all HF patients 3 
report symptoms possibly related to HF during their follow-up visits. NPs are of enormous help 4 
to evaluate whether these symptoms are related to HF and increased intracardiac filling 5 
pressures. This assessment has direct therapeutic consequences and will usually lead to 6 
adjustments of HF medication in case of HF-related symptoms. If NPs concentrations and 7 
therefore filling pressures are in the normal range or only mildly elevated (e.g. BNP below 100 8 
pg/ml or NT-proBNP below 400 pg/ml), symptoms most often do have other causes and 9 
patients can be reassured that they are not related to HF, and measures directed against the more 10 
likely cause can be taken. 11 
 12 
5. Risk stratification of pulmonary embolism and pneumonia 13 
The hemodynamic cardiac stress of the left and right heart combined as quantified by NP 14 
concentrations has been shown to be a powerful predictor of death in both patients with 15 
pulmonary embolism and patients with pneumonia. As a single marker, NPs achieve similar 16 
prognostic accuracy as compared to complex multivariable risk scores. 154,155 Measuring NPs 17 
may therefore help in the appropriate triage, early admission to an intensive care unit, if at high 18 
risk of death, and possibly outpatient management, if at very low risk or death. ESC guidelines 19 
state that NPs should be considered in patients with pulmonary embolism.156 While the use in 20 
pneumonia has not been evaluated in other guidelines, we think that the use of NPs in this 21 
indication might allow the early detection of previously undiagnosed or underestimated cardiac 22 
disease possibly amendable to therapeutic interventions in a relevant proportion of patients with 23 
pneumonia and thereby hopefully ameliorate the substantial mortality observed in pneumonia 24 
and substantially elevated NPs.155,157–164 By contrast, low NPs can rule out any relevant cardiac 25 
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dysfunction. The clinical relevance of NPs in patients with pneumonia and the proper 1 
timing of their measurement should be addressed in future research. 2 
 3 
6. Preoperative risk stratification in non-cardiac surgery 4 
In patients undergoing non-cardiac surgery, judging the risk-benefit ratio of the operation 5 
including post-operative complications is challenging for both the physician as well as the 6 
patient. In this regard, concentrations of BNP and NT-proBNP sampled prior to such surgeries 7 
have been shown to be powerful predictors of post-procedural complications, including death, 8 
myocardial infarction, and acute HF to allow better informed decisions.165–167 9 
Accordingly, current Canadian clinical practice guidelines recommend the 10 
measurement of NPs in patients who are 65 years of age or older, are 45-64 years of age with 11 
significant cardiovascular disease for preoperative risk stratification.165 ESC guidelines state 12 
that NPs may be considered in this indication.168  13 
 14 
7. Other evolving indications 15 
Promising other evolving indications include patients with primary pulmonary hypertension, 16 
patients with congenital heart disease, patients with valvular heart disease, and critically ill 17 
patients in the intensive care unit.169–177 18 
 19 
8. Conclusion 20 
NPs are the gold standard biomarkers for HF diagnosis and prognosis. The measurement of 21 
NPs can help clinicians manage patients in several clinical scenarios. They are helpful in 22 
screening to identify or exclude cardiac disease, for the differential diagnosis of symptoms 23 
27 
 
that might be due to HF and are robust powerful prognostic tools. Each NP has specific cut-1 
off concentrations. Plasma concentrations should be interpreted in the context of the clinical 2 
setting and as a quantitative marker of HF. The incremental value of NP-guided therapy 3 
remains controversial.   4 
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Figure legends 1 
 2 
Figure 1  illustrates the haemodynamic determinants of NPs. 3 
 4 
ANP: atrial natriuretic peptide; BNP: B-type natriuretic peptide; NT-proBNP : N-terminal 5 
proBNP; NP: Natriuretic peptide; LV: left ventricular; RV: right ventricular; HF: heart 6 
failure. 7 
 8 
Figure 2. Diagnostic algorithm for HF. 9 
 10 
NP: Natriuretic peptide; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart 11 
failure with reduced ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; 12 
LVEF: left ventricular ejection fraction; RV: right ventricular; HF: heart failure. 13 
 14 
Figure 3. NP-screening in patients at high cardiovascular risk by GPs and diabetologists is an 15 
integral component of integrated patient care pathways aiming to prevent and/or early detect 16 
cardiovascular disease including heart failure (HF). 17 
 18 
NP: Natriuretic peptide; GP: general practitioner; HFpEF: heart failure with preserved 19 
ejection fraction; HFrEF: heart failure with reduced ejection fraction; LVEF: left ventricular 20 
ejection fraction; RV-HF: right ventricular heart failure; VHD: valvular heart disease. 21 
 22 
  23 
44 
 
Figure 4. All-cause mortality comparison of NT-proBNP–guided versus standard therapy in 1 
chronic HFrEF. 2 
 3 
(A) Forest analysis is shown for all-cause mortality in NT-proBNP–guided versus standard 4 
therapy. (B) Sensitivity analyses were used to assess the impact of sequential removal of 5 
studies on all-cause mortality. CI: confidence interval; GUIDE-IT: Guiding Evidence Based 6 
Therapy Using Biomarker Intensified Treatment in Heart Failure; HFrEF: heart failure with 7 
reduced ejection fraction; NT-proBNP: N-terminal pro–B-type natriuretic peptide; PRIMA: 8 
PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure; 9 
RR: risk ratio; SIGNAL-HF: Swedish Intervention study–Guidelines and NT-proBNP 10 
AnaLysis in Heart Failure; TIME-CHF: Trial of Intensified versus Standard Medical Therapy 11 
in Elderly Patients With Congestive Heart Failure Randomized Trial. 12 

1) HF-Diagnosis: Clinical + ECG + chest x-ray + NP
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